Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial.

Next Previous
Trial Profile

The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramipril (Primary) ; Rosiglitazone (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Death; Diabetes mellitus; Glucose intolerance; Heart failure; Kidney disorders; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms DREAM

Most Recent Events

  • 22 Apr 2011 Results of an analysis following drug withdrawal published in the Diabetes Care.
  • 20 Sep 2006 Status change
  • 14 Sep 2006 Primary endpoint 'Death-rate' has not been met for ramipril according the results presented at the Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top